Post-treatment imaging of musculoskeletal sarcoma remains challenging, but newer imaging techniques are improving our ability to recognize both local and distant recurrence and accurately distinguish local recurrence from post-treatment change. We review recent advances in dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping and positron emission tomography/computed tomography in the post-treatment follow-up of musculoskeletal sarcoma. We also describe our multidisciplinary sarcoma team approach to patient care and the essential role of the radiologist in the clinical follow-up scheme.
The American Cancer Society estimates that soft tissue and bone sarcoma combined will account for 0.9% of new malignant cancer cases in the United States in 2014, with soft tissue sarcoma approximately 4 times more common than bone sarcoma (12,020 new cases vs 3,020 new cases, respectively) [1] . Over the last 12 years a huge amount of data on the molecular and gene biology of these tumours has been uncovered, yielding an exponential increase in our knowledge and understanding of sarcoma behavior and refinement of sarcoma classification, reflected in the newest 2013 World Health Organization classification of tumours of soft tissue and bone [2e4] . Unfortunately, overall patient survival has not yet benefited from this recent gain in knowledge. After a sharp improvement in survival during the 1970s and 1980s following the advent of multidrug chemotherapy, radiotherapy and improved surgical techniques, overall survival rates for sarcoma patients have plateaued over the last 30-40 years [5e8] . According to the most current SEER (Surveillance, Epidemiology, and End Results) Program cancer statistics review, the age-adjusted 5-year survival rate is 65.3% for soft tissue sarcoma and 66.6% for bone sarcoma [9] . This data emphasizes the seriousness of musculoskeletal sarcoma and underscores the importance of systemic and local surveillance in conjunction with coordinated post treatment care to ensure optimal outcome.
Because recurrences usually develop within the first 2 years following therapy [10] , with only 5% developing after 5 years [11e13], follow-up imaging is most aggressive during this early post-treatment period. In this review we present a systematic approach to the imaging of patients following treatment for a musculoskeletal sarcoma, highlighting fundamental concepts, the importance of a systematic coordinated approach, and emphasizing the recent advances in imaging.
Multidisciplinary Sarcoma Teams
Many tertiary care medical centers in the United States have developed multidisciplinary teams of specialized allied health practitioners and physicians, including medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal pathologists, and musculoskeletal radiologists, in the hope of advancing long-term outcomes through coordinated collaboration. The primary therapeutic goal is extending disease-free and overall survival while still maintaining good functional outcome. Some of these teams, including our own, have joined forces across multiple institutions to broaden ideas for optimal management and further enhance individual patient care. Our 12-institution team meets weekly to review a list of patients recently diagnosed or being followed for sarcoma. The primary medical or surgical oncologist for each case presents the patient and then invites input from other medical specialists on areas ranging from diagnosis, imaging evaluation, medical and surgical management options and appropriate follow-up.
The Role of the Radiologist
Whether or not one is a member of a multidisciplinary sarcoma team, the radiologist must have an integral role in the evaluation of patients with suspected musculoskeletal tumours. No one is better suited to determine and assess the appropriate imaging studies required for diagnosis and staging. While the essential value of radiographs in the workup of bone lesions is well established, their importance in the assessment of soft tissue masses is too often underestimated. Although magnetic resonance imaging (MRI) is the favored modality to fully characterize soft tissue masses, radiographs should always be the first imaging study obtained in a patient with a suspected soft tissue mass [14] . Among many other reasons, radiographs are the best method for identifying a skeletal deformity which may masquerade as a mass or detecting mineralization associated with a mass, sometimes suggesting a specific diagnosis (Figures 1 and 2) . Similarly, radiographs, even when negative, are incredibly helpful for correlation with MRI in the evaluation of any lesion. In our experience interpretation of a soft tissue or bone lesion on MRI without comparison radiographs is fraught with danger.
Excisional biopsy or unplanned marginal excision as the initial surgery is an unfortunate reality for many patients ultimately diagnosed with sarcoma, with a significant negative impact on local control and survival. In assessing the effect of unplanned excision in patients with soft tissue sarcoma, Qureshi et al. [15] noted that unplanned excision may occur as the initial surgical procedure in as many as 40% of patients, who then have a twofold increased incidence of local recurrence. As previously emphasized over many different publications, when imaging is not sufficient to suggest a specific diagnosis, a conservative approach is warranted [16] . A clear statement in the radiologist report of the need for orthopedic oncology referral prior to biopsy can help avert such a misadventure. The underlying bone (star) was not involved (C). Given the MR imaging features of a large, deep, soft tissue mass with necrosis, a diagnosis of a sarcoma is highly likely. Based on the additional radiographic findings of calcification and osseous remodeling, a diagnosis of synovial sarcoma was proposed as the primary differential consideration and orthopedic oncology referral was recommended in the report.
Necessary Groundwork
Organized and consistent data collection during protocol of the MRI will optimize the images and interpretation, increasing the value of the radiologist to the treatment team and the patient. We have previously described a systematic approach to the imaging of bone and soft tissue sarcoma patients following therapy [17, 18] . Paramount to this approach is a thorough understanding of the clinical history, including previous therapy, and a review of previous radiographic and advanced imaging studies.
A majority of the relevant clinical history can be gleaned from the pathology and operative reports. Tumour type, grade, size, anatomical location/depth, and surgical margin status all influence the risk of recurrence and should be sought from the reports. Size greater than 10 cm and an inadequate surgical margin are especially worrisome, with poor implications on overall patient outcome [19] . The details of adjuvant radiation or chemotherapy can be more difficult to obtain, but this knowledge is critical for accurately characterizing neoadjuvant treatment response and distinguishing typical post-therapy changes from local tumour recurrence. Recognition of the expected timedependent MRI signal alterations of the soft tissue, muscle and bone within a radiation treatment field ( Figure 3 ) will help avoid misinterpretation [17, 18] .
Comparison to the original pretreatment imaging studies and any interval post treatment imaging is also essential to ensure proper coverage of the anatomy and optimize detection of recurrence. In addition, this review will reveal in advance patients who may need modification of the tumour protocol with special techniques to account for hardware or other artifactual limitations. In today's digital age, clinical reports and prior imaging studies are generally available to retrieve locally or upload from outside media and subsequently review. In a more isolated outpatient imaging center setting, schedulers and/or radiology allied health staff can contact the patient prior to their appointment to ensure the reports and images are brought in and provided to the Figure 2 . Diagnostic value of radiographs following treatment in a 22-year old woman following distal right femoral replacement for high-grade osteoblastic osteosarcoma. Anteroposterior (A) and lateral (B) radiographs of the distal femur 1 year following surgery and neoadjuvant chemotherapy demonstrates a rounded hyperdense mass in the anteromedial soft tissues of the lower right thigh (arrow), suspicious for recurrent osteosarcoma. Axial subtraction image (C) performed 1 week later is limited by metallic artifact from the hardware, but suspicious nodular enhancement is seen in the area of radiographic concern. Contemporary positron emission tomography/computed tomography (PET/CT) (D) demonstrates intense hypermetabolism within the soft tissue mass (arrow), better illustrating its suspicious nature. Recurrent high-grade osteosarcoma was found on biopsy. radiologist for consideration in the protocol. Proactive data acquisition will help reduce call-backs and reporting delays. Figure 4 ) [17, 18, 20, 21] . Reliance on pure anatomical change, such as tumour volume, to qualify therapeutic response can also be misleading, as studies have shown significant interobserver variability in tumour volume measurements pre-and postradiation therapy [22, 23] . Furthermore, two recent studies of soft tissue sarcomas treated with preoperative radiotherapy found that an increase in tumour size or volume had no impact on local recurrence rates or overall survival [24, 25] . Specifically, le Grange et al. [24] found an increase in tumour volume in 12 of 68 (20%) borderline resectable soft tissue sarcoma patients treated with preoperative radiotherapy. A majority (9 of 12) of these expanding tumours showed diffuse necrosis pathologically and all 12 had negative surgical margins and no local relapse. Similarly, persistent enhancement within treated tumours on routine T1 post contrast images does not always indicate viable tumour or poor response (Figure 4 ). In fact, Roberge et al. [23] found positive treatment effects in the form of hyaline fibrosis and granulation tissue, both of which enhance, in tumours that were considered nonresponsive by imaging. In the quest to better categorize tumour response to neoadjuvant therapy and better differentiate post-treatment change from recurrent tumour, PET/CT and the addition of newer functional MR techniques, such as dynamic contrastenhanced (DCE) MRI and diffusion weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping, to routine MR sequences have proved useful and remain under investigation at several institutions. Ultimately, the goal is to find the most accurate and cost-effective post-therapy imaging algorithm. Due to relatively high technical demands, MR spectroscopy, while promising, is currently primarily a research tool and will not be discussed [26, 27] .
Local Tumour Recurrence
DCE-MRI is a functional technique that can be used to highlight the neoangiogenesis properties of nonresponsive or recurrent malignancy ( Figure 5 ), which typically manifests on postprocessing time-signal intensity curves with rapid arterial perfusion in both bone [28] and soft tissue sarcomas [29] . A recent well-referenced paper by Fayad et al. [26] describes various additional DCE-derived quantitative endpoints, such as K trans and k ep , which can be used to distinguish viable tumour from more slowly-enhancing post-treatment fibrosis. In fact, good treatment response based on DCE-MRI vascular pharmacokinetics can be detected as early as 2 days after the first treatment [30] . In a more recent 2013 study, Meyer et al. [31] were able to identify perfusion changes using K trans in soft tissue sarcomas 2 weeks after initiation of sorafenib chemotherapy, with positive correlation to histologic response. Given these findings, there is potential to alter or forego chemotherapy regimens in nonresponders very early in the neoadjuvant cycle. However, analysis of these parameters is time-consuming, and for many nonacademic or busy academic radiology practices this would be untenable. The quickest and most straightforward method for discrimination is analysis of composite DCE-MRI maximum intensity projection (MIP) images of the tumour volume that are derived over a total imaging time of 5 minutes [26] . In a separate study, these investigators were able to accurately detect positive treatment response in osteosarcoma and highgrade soft tissue sarcoma using the MIP images alone, with positive histologic correlation [32] . In regards to discrimination of recurrent tumour from post-treatment change following definitive surgery, Del Grande et al. [33] showed that conventional plus DCE-MRI increased the accuracy of recurrence detection to 97%, compared to 27% with conventional images alone. In both the Fayad et al. and standard tumour protocol increased the overall scan time by only 5 minutes. Widespread reproducibility of DCE-MRI remains a question due to protocol nonuniformity across institutions and tumour heterogeneity, amongst other reasons [34] . DWI with ADC mapping is able to accentuate the restriction of water Brownian motion within malignancies compared to benign processes by persistence of hyperintensity at progressively higher B values, with corresponding low signal on the ADC map. Extracting differences in diffusion restriction has proven helpful in the evaluation of neoadjuvant treatment efficacy in both bone and soft tissue sarcoma [34e44]. A general increase in the post-treatment ADC value when compared to the pretreatment value suggests a positive Figure 6 . Diffusion weighted imaging (DWI) in a 73-year-old woman with a right retroperitoneal leiomyosarcoma treated with 5750 cGy neoadjuvant radiation therapy, with 20% viable tumour identified following operative resection. Axial apparent diffusion coefficient (ADC) map of the abdomen at presentation (A) demonstrates the tumour intimately associated with the medial aspect of the right kidney. The oval region of interest (ROI) revealed a mean ADC value of 1.07 Â 10 À3 mm 2 /s. A similar oval ROI drawn on the axial ADC map obtained 2 weeks following the conclusion of neoadjuvant radiotherapy (B) yielded a value of 1.44 Â 10 À3 mm 2 /s. The increase in ADC value following treatment indicates a positive response to treatment, which was reflected on the final pathology. response ( Figure 6 ). In comparison, relatively few studies have addressed DWI in the postoperative setting [26, 33, 45] , but the largest study on the topic found that comparison of ADC values could distinguish recurrence from postoperative hematomas or scar [33] (Figure 7) . Unfortunately, there is no standardization for DWI protocols with ADC mapping across institutions, hindering the ability to establish reliable cutoff ADC values [46] . In addition to the lack of standardization, Subwahong et al. [46] describe other important pitfalls to consider when using DWI, including greater susceptibility artifacts at tissue boundaries with 3T, low sensitivity of DWI to sclerotic bone lesions due to normal low intensity of background marrow, overlap of low ADC values between tumour and benign hematoma or fat, and DWI neoplastic mimickers, such as abscess. At this time, the consensus is that DWI with ADC mapping is a helpful adjunct to conventional and DCE-MRI for further characterization and confirmation of malignancy [26, 32, 33] . At our institution, DWI acquisition adds 5 minutes to the overall scan time.
Several studies have shown that post-treatment PET/CT can reliably predict neoadjuvant therapy response in bone and soft tissue sarcoma [47e50]. In a pooled meta-analysis of 8 bone sarcoma studies, Hongtao et al. [51] found that an SUV <2.5 after preoperative chemotherapy correlated with positive histologic response in osteosarcoma. Furthermore, Eary et al. [52] have found that comparison of FDG uptake at initial presentation, mid-therapy and post-therapy can independently prognosticate patient outcome in both bone and soft tissue sarcoma. Byun et al. [37] are also actively investigating PET/MRI for its potential role in forecasting neoadjuvant therapy response.
Metastasis Surveillance
Distant metastasis continues to plague the prognosis in both bone and soft tissue sarcoma. The 5-year survival in osteosarcoma decreases from 67% to 20% in the setting of metastatic disease [53] , which develops most commonly in the lung (28% of patients by 5 years) and bone (8%-10%) [54, 55] . Similarly, soft tissue sarcoma has a distant metastatic rate of 22%-36% [56, 57] , also most often to the lung, with a median overall survival of just 12 months [54, 55, 58, 59] . Improving patient prognosis requires early and accurate exposure of local and distant recurrence to facilitate appropriate and timely management decisions or alterations [50] .
FDG PET/CT is a comprehensive imaging modality that simultaneously allows assessment of both the local operative site ( Figure 2D ) and potential distant sites of recurrence ( Figure 8 ). Two recent multistudy meta-analyses concluded that PET/CT had a high restaging accuracy in patients with Ewing sarcoma family tumours (ESFT) [60] and osteosarcoma [53] . Although the focus in both metaanalyses was of bone tumours, many of the studies that were scrutinized had also simultaneously evaluated PET/ CT for soft tissue tumours, also demonstrating high accuracy in this group. Specifically, PET/CT is superior for detection of bone metastases when compared to bone scintigraphy and for detection of nodal/soft tissue metastases when compared to CT or MRI. However, both metaanalyses identify spiral CT as the most accurate modality for the evaluation of lung metastases. In a study of 30 patients with either bone or soft tissue sarcoma that compared CT chest to PET/CT, Iagaru et al. [61, 62] found that PET/CT was false negative in 3 of 8 pathologicallyconfirmed pulmonary metastases, all of which were >1 cm. The authors concluded that lung metastases cannot be confidently excluded with PET/CT alone.
An additional benefit of PET/CT during the restaging process is that it provides an adjunct to operative bed surveillance for local recurrence, and can be a helpful problem-solving tool in cases where the anatomic imaging is equivocal [63] . However, greater incorporation of functional MR techniques into tumour protocols, particularly DCE-MRI, will likely lessen the need for multimodality clarification. Of note, PET/CT should be avoided for at least the first 3 postoperative months to allow the expected hypermetabolism of post-treatment change to dissipate [47, 48, 61, 62, 64] .
Post-treatment Imaging Follow-up
Although close interval imaging follow-up is a generally accepted practice for patients with sarcoma, specific imaging follow-up recommendations noted in radiology reports can provide helpful reinforcement. American College of Radiology (ACR) Appropriateness Criteria [65] for the follow-up of malignant or aggressive musculoskeletal tumours, last updated in 2011, advocate frequent local and systemic surveillance in high-risk soft tissue sarcoma patients, defined as patients with extremity tumours >5 cm and trunk/retroperitoneal tumours of any size. Local and systemic surveillance intervals of every 3 months for 2 years, every 4 months for the next 2 years, every 6 months for the fifth year, and then annually for years 5-10 are recommended for high-risk patients [65, 66] . In a study of 165 soft tissue sarcoma patients published in 2012 by Chou et al. [67] , close interval follow-up in high-risk patients (size >5 cm, deepseated, grade II or III, margin <10 mm) was associated with better overall disease specific survival. Extremity soft tissue sarcomas <5 cm are generally considered low-risk and follow-up can be determined on a case-by-case basis.
General imaging guidelines for local disease surveillance in patients with bone sarcoma are radiographs every 3-6 months for at least 5 years, and then annually thereafter up to 10 years. MRI appropriately modified for metal suppression may also be utilized at close intervals in higherrisk patients. Chest CT every 3-6 months for at least 5 years is advocated for distant disease surveillance. PET/CT has recently been shown to be superior to bone scintigraphy and conventional anatomic imaging for evaluation of metastasis to nonpulmonary sites [15, 60] .
In summary, the evaluation of patients following treatment for musculoskeletal sarcoma remains challenging. As was true in the Middle Ages in the famous quote credited to Francis Bacon, ''knowledge is power'' [68] . Nothing could be more true in assessing the sarcoma patient following treatment. Knowledge of the clinical and operative history, preoperative appearance of the tumour, and details of treatment will allow optimal results.
